Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseases
- Industry expert Ulrik Mouritzen M.D. appointed Chief Executive Officer
- Funding to advance lead asset to phase 1b clinical trial and further build pipeline
COPENHAGEN, Denmark, Nov. 10, 2022 /PRNewswire/ — Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces it has emerged from stealth after closing a seed financing of EUR 4 million led by Novo Holdings and Sound Bioventures.
Diabetic retinopathy (DR) affects approximately 30% of all patients with diabetes and is the leading cause of blindness among working-age adults. Age-related macular degeneration (AMD) affects approximately 25% of people older than 60 years of age and is the leading cause of blindness within the elderly population. Breye has two novel and relevant oral therapies to address both DR and AMD.
